Cambridge, UK, 02 March 2020: PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.

CAMBRIDGE, UK, 02 March 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital. Existing investors, Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, Cambridge Consultants Ltd, Rising Tide Fund, and Civilization Ventures, also all participated in the round.

Click here for the February 2020 edition of eNews. 

Christopher Good, Director of Cell and Gene Therapy Logistics at Biocair, will explore ongoing material sourcing challenges for organisations moving from development to clinical and commercial manufacturing in an upcoming webinar taking place on 12 March 2020.

Critical considerations in ensuring patient access to cell and gene therapies, and continued industry growth, include proper understanding of how to manage source material quality and supply chain continuity. The following areas will be covered:

Cambridge, UK, 25th February 2020 / Sciad Newswire / One Nucleus is pleased to announce the launch of  a new careers conference in

Cambridge UK: 26 February 2020: Cerba Research has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.

The EZ PREP efficiently isolate highly purified peripheral blood mononuclear cells from AMSBIO is designed to efficiently isolate highly purified peripheral blood mononuclear cells (PBMCs) from fresh whole blood products by density gradient centrifugation.

The unique EZ PREP tube design provides greater visibility of your target cell population, allowing you to maximise your recovery of mononuclear cells. As a result, PBMCs are immediately available for downstream applications such as flow cytometry, culture, and/or DNA/RNA isolation.

Cambridge and Leeds, UK, 25th February 2020 / Sciad Newswire / Domainex Ltd., a fully integrated provider of drug discovery services from its Medicines Research Centre near Cambridge, UK, has entered into a research partnership with LUNAC Therapeutics Limited to discover novel anticoagulant therapies that have a reduced risk of bleeding compared to current therapies.

Arecor Achieves Second License Milestone Payment from Global Pharmaceutical Partner

Arecor formulated biosimilar product progressing through clinical studies

Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

Colleagues from TTP will be supporting and attending this one-day matchmaking event - do not miss it.

Information from the organisers: Imperial College London, NIHR and the NHS


Less than 1% of proposed Biomarkers achieve clinical adoption and there is a wide gulf between those published in academic journals and those being translated onto scalable platforms that can be integrated into healthcare systems.